Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
- no estimate extracted15 participantsVery low
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (high certainty).
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (high certainty).
Capecitabine‐containing regimens probably leads to lower progression‐free survival (PFS)median compared with chemotherapy regimens without capecitabine (moderate certainty).
Capecitabine‐containing regimens probably leads to lower PFS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in PFS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in objective response rate compared with chemotherapy regimens without capecitabine (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.